Optimal Management of Moderate to Severe Atopic Dermatitis: Infants, Adults, and Everyone in Between

Moderate to severe atopic dermatitis (AD) can present in infants and persist through adulthood, impacting quality of life, social interactions, mental health, and result in undue financial burden.  Join this live webinar to hear expert faculty recommendations on how recently approved agents can improve patient and disease outcomes in uncontrolled moderate to severe AD.

Agenda

Welcome

Recent advances in AD for infants and young children

Recent advances in AD for tweens and teens

Recent advances in AD for adults

Closing remarks

Question and answer session

Faculty

Faculty
Robert Sidbury, MD, MPH

Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Faculty
Jonathan Silverberg, MD

Associate Professor, Dermatology
Director of Clinical Research
Director of Patch Testing

George Washington University School of Medicine and Health Sciences
Washington, DC

Program Overview
Moderate to severe atopic dermatitis (AD) can present in infants and persist through adulthood, impacting quality of life, social interactions, mental health, and result in undue financial burden. Join this live webinar to hear expert faculty recommendations on how recently approved agents can improve patient and disease outcomes in uncontrolled moderate to severe AD.

Goal Statement
The goal of this educational program is to improve learners’ knowledge and competence regarding improving the management of pediatric and adult patients with moderate to severe atopic dermatitis.

Target Audience
This education is intended for dermatologists, allergists, nurse practitioners, physician associates/physician assistants, nurses, and other healthcare professionals who treat pediatric and adult patients with moderate to severe atopic dermatitis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review efficacy and safety data for infants and young children, tweens and teens, and adults with moderate to severe AD
  • Select optimal therapy for patients with moderate to severe AD based on indication and efficacy and safety data
  • Develop treatment plans for patients with moderate to severe AD based on patient age and patient/caregiver preferences and goals

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.